[go: up one dir, main page]

MXPA03006549A - Uso de la dapsona como neuroprotector en el infarto cerebral. - Google Patents

Uso de la dapsona como neuroprotector en el infarto cerebral.

Info

Publication number
MXPA03006549A
MXPA03006549A MXPA03006549A MXPA03006549A MXPA03006549A MX PA03006549 A MXPA03006549 A MX PA03006549A MX PA03006549 A MXPA03006549 A MX PA03006549A MX PA03006549 A MXPA03006549 A MX PA03006549A MX PA03006549 A MXPA03006549 A MX PA03006549A
Authority
MX
Mexico
Prior art keywords
dapsone
cerebral infarction
neuroprotective
infarction
suffered
Prior art date
Application number
MXPA03006549A
Other languages
English (en)
Inventor
Kravzov Jinich Jaime
Original Assignee
Univ Autonoma Metropolitana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34075071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03006549(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Autonoma Metropolitana filed Critical Univ Autonoma Metropolitana
Priority to MXPA03006549A priority Critical patent/MXPA03006549A/es
Priority to PCT/MX2004/000018 priority patent/WO2005007239A1/es
Priority to JP2006521015A priority patent/JP5452844B2/ja
Priority to HK07104433.0A priority patent/HK1098086B/xx
Priority to DE602004006633T priority patent/DE602004006633T2/de
Priority to EP04721040A priority patent/EP1655055B1/en
Priority to BRPI0412212-7A priority patent/BRPI0412212A/pt
Priority to CNB2004800264451A priority patent/CN100500246C/zh
Priority to EA200600272A priority patent/EA012174B1/ru
Priority to AT04721040T priority patent/ATE362783T1/de
Priority to PT04721040T priority patent/PT1655055E/pt
Priority to CA2533181A priority patent/CA2533181C/en
Priority to ES04721040T priority patent/ES2287713T3/es
Priority to US10/565,309 priority patent/US8268893B2/en
Publication of MXPA03006549A publication Critical patent/MXPA03006549A/es
Priority to EC2006006316A priority patent/ECSP066316A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

La presente invencion, tiene por objeto demostrar el uso de la dapsona como el primer tratamiento eficaz contra las consecuencias incapacitantes asociadas con el infarto cerebral en estos pacientes. La dapsona fue evaluada como neuroprotector, en el modelo de infarto cerebral producido por la oclusion de la arteria cerebral media en las ratas y en pacientes que sufrieron un infarto cerebral agudo por trombo-embolismo: En ambos estudios la dapsona demostro una reduccion de entre 70 y 90% de las consecuencias adversas que se presentan como consecuencia del infarto.
MXPA03006549A 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral. MXPA03006549A (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.
US10/565,309 US8268893B2 (en) 2003-07-22 2004-03-16 Use of dapsone as a neuroprotector in cerebral infarction
BRPI0412212-7A BRPI0412212A (pt) 2003-07-22 2004-03-16 uso da dapsona como neuroprotetor no infarto cerebral
EA200600272A EA012174B1 (ru) 2003-07-22 2004-03-16 Применение дапсона в качестве нейропротектора при остром церебральном инфаркте
HK07104433.0A HK1098086B (en) 2003-07-22 2004-03-16 Use of dapsone as a neuroprotector in preparing medicament for brain stroke
DE602004006633T DE602004006633T2 (de) 2003-07-22 2004-03-16 Verwendung von dapson als neuroprotektor bei zerebralinfarkt
EP04721040A EP1655055B1 (en) 2003-07-22 2004-03-16 Use of dapsone as a neuroprotector in cerebral infarction
PCT/MX2004/000018 WO2005007239A1 (es) 2003-07-22 2004-03-16 Uso de la dapsona como neuroprotector en el infarto cerebral
CNB2004800264451A CN100500246C (zh) 2003-07-22 2004-03-16 氨苯砜作为神经保护剂在制备脑中风药物中的应用
JP2006521015A JP5452844B2 (ja) 2003-07-22 2004-03-16 脳梗塞における神経プロテクターとしてのダプソンの使用方法。
AT04721040T ATE362783T1 (de) 2003-07-22 2004-03-16 Verwendung von dapson als neuroprotektor bei zerebralinfarkt
PT04721040T PT1655055E (pt) 2003-07-22 2004-03-16 Utilização de dapsona como um neuroprotector em acidente vascular cerebral.
CA2533181A CA2533181C (en) 2003-07-22 2004-03-16 Use of dapsone as neuroprotector in the brain stroke
ES04721040T ES2287713T3 (es) 2003-07-22 2004-03-16 Uso de la dapsona como neuroprotector en el infarto cerebral.
EC2006006316A ECSP066316A (es) 2003-07-22 2006-01-25 Uso de la dapsona como neuroprotector en el infarto cerebral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.

Publications (1)

Publication Number Publication Date
MXPA03006549A true MXPA03006549A (es) 2004-03-18

Family

ID=34075071

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.

Country Status (14)

Country Link
US (1) US8268893B2 (es)
EP (1) EP1655055B1 (es)
JP (1) JP5452844B2 (es)
CN (1) CN100500246C (es)
AT (1) ATE362783T1 (es)
BR (1) BRPI0412212A (es)
CA (1) CA2533181C (es)
DE (1) DE602004006633T2 (es)
EA (1) EA012174B1 (es)
EC (1) ECSP066316A (es)
ES (1) ES2287713T3 (es)
MX (1) MXPA03006549A (es)
PT (1) PT1655055E (es)
WO (1) WO2005007239A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
KR101875705B1 (ko) 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104069091A (zh) * 2014-07-09 2014-10-01 崔德华 氨苯砜在保护血脑屏障完整性中的应用
KR20160047318A (ko) * 2014-10-22 2016-05-02 삼성전자주식회사 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도
KR20200107899A (ko) * 2019-11-16 2020-09-16 이종훈 알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
BR9912062A (pt) * 1998-07-15 2001-04-03 Hassan Jomaa Compostos orgânicos fosforosos e seu uso
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
EP1655055A1 (en) 2006-05-10
CA2533181C (en) 2012-08-07
HK1098086A1 (zh) 2007-07-13
DE602004006633D1 (de) 2007-07-05
PT1655055E (pt) 2007-08-31
CN1852749A (zh) 2006-10-25
CA2533181A1 (en) 2005-01-27
WO2005007239A1 (es) 2005-01-27
JP5452844B2 (ja) 2014-03-26
EP1655055B1 (en) 2007-05-23
EA012174B1 (ru) 2009-08-28
WO2005007239B1 (es) 2005-05-06
US8268893B2 (en) 2012-09-18
DE602004006633T2 (de) 2008-01-31
ECSP066316A (es) 2006-10-25
ES2287713T3 (es) 2007-12-16
ATE362783T1 (de) 2007-06-15
JP2006528175A (ja) 2006-12-14
BRPI0412212A (pt) 2006-08-22
CN100500246C (zh) 2009-06-17
US20100063159A1 (en) 2010-03-11
EA200600272A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
GB0225475D0 (en) Therapeutic agents
GB0225474D0 (en) Therapeutic agents
GEP20084447B (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
GB0018527D0 (en) Composition
PT1594833E (pt) Derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
GB0223038D0 (en) Therapeutic compounds
GB0318447D0 (en) Therapeutic agents
PL377587A1 (pl) Pochodne hydroksyetyloaminy do leczenia choroby Alzheimera
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
BG105575A (en) Method and agent for the treatment of cerebral ischaemia
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
WO2004082706A3 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
GB0328900D0 (en) Novel compounds
ZA200109322B (en) A new use for deferiprone.
MXPA03006549A (es) Uso de la dapsona como neuroprotector en el infarto cerebral.
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2005034857A8 (en) Methods and compositions comprising diamines as new anti-tubercular therapeutics
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof

Legal Events

Date Code Title Description
GD Licence granted
GD Licence granted
GB Transfer or rights
FG Grant or registration
GD Licence granted